PepGen Inc.
24.1M
$118.53M
-3.07
$-2.12
No price alerts set. Add an alert to get notified!
-3.07
1.86
$-2.12
-60.81%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ALEC
Alector, Inc.
|
$2.15 | 6.44% | -1.55 | $237.28M | 1.18 |
|
APLT
Applied Therapeutics, Inc.
|
$0.10 | 0.00 | -0.83 | $14.86M | -4.46 |
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
$9.42 | 9.53% | -1.60 | $118.08M | 0.01 |
|
CRDF
Cardiff Oncology, Inc.
|
$1.63 | 4.84% | -2.37 | $111.09M | 0.02 |
|
CYBN
Cybin Inc.
|
$8.28 | 1.22% | -1.51 | $413.02M | 0.00 |
|
ELTX
Elicio Therapeutics, Inc.
|
$10.51 | 4.22% | -4.07 | $193.25M | 3.12 |
|
FATE
Fate Therapeutics, Inc.
|
$1.21 | 6.64% | -1.05 | $140.10M | 0.38 |
|
MOLN
Molecular Partners AG
|
$3.93 | 0.64% | -1.89 | $147.03M | 0.05 |
|
NKTX
Nkarta, Inc.
|
$2.11 | 5.25% | -1.50 | $150.07M | 0.24 |
|
SAVA
Cassava Sciences, Inc.
|
$1.96 | -1.76% | -0.90 | $94.44M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$7.80
$0.88
$0.00
0.00%
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
